Bioventus Inc.

Bioventus Inc.(BVS)股票分析

$14.960

-0.079 (-0.53%)收盘时

Loading chart…
最高
15.090
开盘
14.940
成交量加权均价
14.94
成交量
387.05K
市值
365.09M
最低
14.762
成交额
5.78M
企业价值/息税折旧摊销前利润(TTM)
10.16

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.

AI 分析 of Bioventus Inc. (BVS)

买入

Bioventus Inc (BVS) is a good buy right now due to its current price of $14.96, which is below the analyst price target of $18. The company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +107.49%. However, a key risk is the recent strategic review initiated by the board, which could impact investor confidence.

估值指标

Bioventus Inc.(BVS)当前预期市盈率为 14.79,5 年平均预期市盈率为 21.50。

预期市盈率

合理
5 年均值 P/E
21.50
当前P/E
14.79
高估
53.09
低估
-10.09

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
8.82
当前EV/EBITDA
10.16
高估
10.92
低估
6.72

预期市销率

高估
5 年均值 P/S
0.87
当前P/S
1.59
高估
1.28
低估
0.46

Alphio AI 对 BVS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BVS

$7.26

情景价格

基

基准

基准 · 50%BVS

$5.98

情景价格

悲

悲观

悲观 · 25%BVS

$5.88

情景价格

持有 BVS 的大户

P

Pinnacle Investment Management Group Limited

+ 持有BVS

-14.16%

3个月收益率

事件时间线

2026-08-05 (ET)

08:30:00

Bioventus Initiates Review of Strategic Alternatives

2026-06-30 (ET)

14:00:00

AWS Invests $1 Billion to Establish Forward Deployed Engineering Organization

2026-05-06 (ET)

08:10:00

Bioventus Raises FY26 Revenue Guidance to $600M

08:10:00

Bioventus Q1 Revenue $132.09M, Exceeds Expectations

2026-03-05 (ET)

07:20:00

Bioventus Reports Q4 Revenue of $157.9M, Beating Expectations

资讯

BVS 常见问题 —— 由 Alphio AI 解答

Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Bioventus Inc (BVS) is a good buy right now due to its current price of $14.96, which is below the analyst price target of $18. The company has shown strong financial performance with a gross margin of 68.29% in Q2 2026 and a year-to-date change of +107.49%. However, a key risk is the recent strategic review initiated by the board, which could impact investor confidence.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易